CELEX: 62021TA0194
Language: en
Date: 2021-12-21 00:00:00
Title: Case T-194/21: Judgment of the General Court of 21 December 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE) (EU trade mark — Opposition proceedings — International figurative registration designating the European Union — Figurative mark HYALOSTEL ONE — Earlier EU word mark HYALISTIL and earlier figurative mark HyalOne — Earlier international word mark HYALO — Relative ground for refusal — Article 8(1)(b) of Regulation (EU) 2017/1001 — Obligation to state reasons)

28.2.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 95/33
            
         
      Judgment of the General Court of 21 December 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE)
      (Case T-194/21) (1)
      
      (EU trade mark - Opposition proceedings - International figurative registration designating the European Union - Figurative mark HYALOSTEL ONE - Earlier EU word mark HYALISTIL and earlier figurative mark HyalOne - Earlier international word mark HYALO - Relative ground for refusal - Article 8(1)(b) of Regulation (EU) 2017/1001 - Obligation to state reasons)
      (2022/C 95/45)
      Language of the case: English
      
         Parties
      
      
         Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers)
      
         Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and V. Ruzek, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO: Stelis Biopharma Ltd (Karnataka, India)
      
         Re:
      
      Action brought against the decision of the Fifth Board of Appeal of EUIPO of 27 January 2021 (Case R 831/2020-5), relating to opposition proceedings between Fidia Farmaceutici and Stelis Biopharma.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Annuls the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 27 January 2021 (Case R 831/2020-5);
               
            
                  2.
               
               
                  Orders EUIPO to bear its own costs and to pay those incurred by Fidia farmaceutici SpA in connection with the present proceedings.
               
            
         (1)  OJ C 217, 7.6.2021.